Garlic oil and its primary component, diallyl disulphide (DADS), were tested in rats with isoprenaline (ISO) induced myocardial infarction for cardioprotective benefits when combined with carvedilol. Garlic oil (GO) was administered to rats (Sprague-dawley strain) at two doses of 50 and 100Â mg/kg body weight, whereas DADS was given in two doses of 4.47 and 8.94Â mg/kg, respectively. The animals were given oral doses of garlic oil and DADS on alternate days for 3Â weeks, either alone or in combination with carvedilol (2Â mg/kg). Cardiac injury was done by administering two doses of isoprenaline (150Â mg/kg, sc) to all treated groups except the first, which served as a control. Biomarkers of cardiac injury and histological investigations were studied for their potential in reducing ISO-induced myocardial damage. Animals pretreated with GO, DADS, and carvedilol had significantly (p < 0.01) lowered heart weight and heart to body weight ratio. In rats treated with carvedilol plus high dosages of garlic oil (100Â mg/kg, p.o) and DADS (8.94Â mg/kg, p.o) compared to the ISO control and carvedilol group, the activities of SOD and Catalase were enhanced in cardiac tissue homogenate. When compared to ISO control and carvedilol group, the activities of LDH and CK-MB were elevated in heart tissue homogenate with a simultaneous reduction in their serum levels in animals treated with a combination of carvedilol with high doses of garlic oil (100Â mg/kg, p.o) and DADS (8.94Â mg/kg, p.o). Overall, combining garlic oil or DADS with carvedilol improved the cardioprotective effect of carvedilol and protected rats from ISO-induced myocardial infarction. However, more research is needed to establish the mechanism of garlic oil and DADS interaction with carvedilol.
The Potential Benefits of Using Garlic Oil and Its Active Constituent, Dially Disulphide, in Combination With Carvedilol in Ameliorating Isoprenaline-Induced Cardiac Damage in Rats.
阅读:8
作者:Asdaq Syed Mohammed Basheeruddin, Challa Obulesu, Alamri Abdulhakeem S, Alsanie Walaa F, Alhomrani Majid, Asad Mohammed
| 期刊: | Frontiers in Pharmacology | 影响因子: | 4.800 |
| 时间: | 2021 | 起止号: | 2021 Sep 27; 12:739758 |
| doi: | 10.3389/fphar.2021.739758 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
